Glenmark to launch cancer drug Zanubrutinib in India
New Delhi: Glenmark Pharmaceuticals on Monday said it will launch cancer treatment drug zanubrutinib in India following approval by the Drugs Controller General of India (DCGI).
Zanubrutinib will be marketed in India under the brand name Brukinsa.
It is the first and only Bruton's tyrosine kinase (BTK) inhibitor approved in India for the treatment of five distinct B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma.
"We look forward to bringing Brukinsa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines)," Glenmark Pharmaceuticals President and Business Head - India Formulations Alok Malik said.
The launch marks a significant milestone in our innovative oncology portfolio, offering patients in India access to a globally trusted therapy with proven efficacy and safety, he added. Glenmark shares on Monday ended 0.68 per cent up at ₹ 1,600.85 apiece on BSE.
In March, Glenmark Pharmaceuticals had launched a medication for glycemic control and weight-loss for diabetes patients.
The Mumbai-based drug firm launched Empagliflozin, a widely recognised SGLT2 inhibitor, under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)''Glempa-L (Empagliflozin 10/25 mg Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg Metformin 500/1000 mg).
The medications are designed to improve glycemic control in adults with type 2 diabetes mellitus while also reducing cardiovascular outcomes in patients with cardiovascular risk.
Studies have demonstrated several benefits of Empagliflozin, including effectively improving glycemic control, supporting weight-loss, and reducing cardiovascular-renal risks in patients with type 2 diabetes mellitus.
Empagliflozin has also demonstrated benefits in heart failure patients by lowering the cardiovascular death or hospitalisation.
"The launch of Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage type 2 diabetes mellitus with established cardiovascular disease more effectively," Glenmark Pharmaceuticals President and Head of India Formulations Business Alok Malik had said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Glenmark Pharma rises 2% as company to launch blood cancer treatment drug
Glenmark Pharma share price rose 1.7 per cent in trade on Tuesday, June 10, 2025, logging an intraday high at ₹1,626.6 per share on BSE. At 10:30 AM, Glenmark Pharma shares were trading 1.56 per cent higher at ₹1,623.35 per share on the BSE. In comparison, the BSE Sensex was up 0.05 per cent at 82,482.52. The company's market capitalisation stood at ₹45,811.07 crore. Its 52-week high was at ₹1,830.05 per share and 52-week low was at ₹1,176 per share. In the past one year, Glenmark shares have gained 33 per cent as compared to Sensex's rise of around 8 per cent. What is boosting rally in Glenmark Pharma shares? The stock gained after the company announced the upcoming launch of zanubrutinib, under the brand name Brukinsa in India. Brukinsa, developed by global oncology company BeOne Medicines (formerly BeiGene), is an orally available Bruton's tyrosine kinase (BTK) inhibitor designed to treat multiple types of B-cell blood cancers. It is the first and only BTK inhibitor approved in India for five types of B-cell malignancies. According to the filing, Brukinsa has already been approved in more than 70 countries, with clinical efficacy demonstrated through trials such as ALPINE, ASPEN and SEQUOIA. Its entry into the Indian market addresses a critical need for new and effective blood cancer treatments. The drug offers a unique pharmacological profile with high response rates and durable disease control across multiple B-cell malignancies. It allows a flexible dosing schedule—once or twice daily—tailored to patient needs. In the ALPINE trial for relapsed or refractory chronic lymphocytic leukaemia (CLL), Brukinsa showed a lower incidence of serious cardiac side effects compared to ibrutinib, a widely used targeted therapy. Fewer patients discontinued Brukinsa due to heart-related complications. About Glenmark Pharmaceuticals Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. About BeOne Medicines BeOne Medicines, formerly known as BeiGene, is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide.
News18
2 days ago
- News18
Stocks To Watch: Wipro, Tata Power, Jana SFB, Tech Mahindra, Zomato, And Others
Last Updated: Stocks to watch: Shares of firms like Wipro, Tata Power, Jana SFB, Tech Mahindra, Zomato, and others will be in focus on Tuesday's trade Stocks to Watch on June 10, 2025: Markets started the week on a strong footing, extending Friday's rally and gaining nearly half a percent. In today's session, stocks like Wipro, Motilal Oswal, Jana Small Finance Bank (SFB), Force Motors, and Tech Mahindra will be in focus amid key developments. Wipro Promoter entity Azim Premji Trust has sold 20.23 crore shares of Wipro worth Rs 5,057 crore through a block deal. Motilal Oswal The Securities and Exchange Board of India (SEBI) has imposed a Rs 3 lakh fine on Motilal Oswal Financial Services (MOFSL) for regulatory violations. Tech Mahindra Lakshmanan Chidambaram, President of Tech Mahindra Americas' strategic vertical business, has announced his retirement effective June 30. Zomato Parent company Eternal has introduced a new long-distance fee for restaurant partners on orders beyond 4 km, aimed at enhancing profitability and improving delivery partner payouts. Tata Power Tata Power announced that its subsidiary, TP Solar, has surpassed 4 GW of solar module output at its Tamil Nadu plant, producing a cumulative 4,049 MW of solar modules and 1,441 MW of solar cells as of May 31, 2025. Zee Entertainment has entered into a strategic equity partnership with start-up Bullet, co-founded by Azim Lalani and Saurabh Kushwah. This marks Zee's first investment since its shift to a content and technology company. Glenmark Pharmaceuticals Glenmark is preparing to launch Zanubrutinib, branded as 'Brukinsa,' in India after receiving approval from the Drugs Controller General of India (DCGI). The drug is a significant advancement in treating certain blood cancers. Mahindra & Mahindra Mahindra & Mahindra has increased its stake in Mahindra & Mahindra Financial Services (MMFSL) through the allotment of shares in MMFSL's rights issue. Jana Small Finance Bank Jana SFB has filed an application with the Reserve Bank of India (RBI) to transition from a small finance bank to a universal bank, in line with RBI's licensing guidelines. Vishnu Prakash R Punglia (VPRPL) CARE Ratings has downgraded VPRPL's ratings and outlook on its short and long-term bank facilities, revising the long-term rating to CARE BBB with a negative outlook from CARE BBB+ with a stable outlook. Disclaimer:Disclaimer: The views and investment tips by experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions. First Published: June 10, 2025, 07:41 IST
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
AMR crisis: Centre asks states to monitor antibiotic use in animals
In an effort to tackle the growing problem of antimicrobial resistance (AMR), which is estimated to claim 2 million lives in India by 2050, the Central Drugs Standard Control Organisation (CDSCO) has asked all state drug controllers to support the development of an antimicrobial use (AMU) reporting framework. The aim is to strengthen monitoring of antibiotic use in animals. For the first time, a joint working group will be formed, comprising representatives from the CDSCO, state licensing authorities (SLAs), and the Department of Animal Husbandry and Dairying (DAHD), to facilitate the implementation of the framework. Officials in the know said the framework will focus on the systematic collection of data on the sale, manufacture, and import of antibiotics for veterinary use. This move follows the Centre's release of the Standard Veterinary Treatment Guidelines for Livestock and Poultry (SVTG) in October last year. The guidelines emphasise minimising antibiotic use to prevent AMR in animals, mirroring similar efforts in human health. They provide symptomatic treatment guidance until a disease is laboratory-confirmed, ensuring minimal or no antibiotic use unless necessary. AMR occurs when bacteria, viruses, fungi and parasites no longer respond to antimicrobial medicines used to treat humans and animals. According to the World Health Organisation (WHO), around 10 million deaths are projected globally by 2050, with India expected to account for 2 million. In 2019, AMR was directly responsible for 1.27 million deaths globally, while 4.95 million were associated with drug-resistant infections. The WHO notes that the emergence and spread of AMR is accelerated by human activity — mainly the misuse and overuse of antimicrobials to treat, prevent, or control infections in humans, animals, and plants. Vegetables, poultry, and dairy products may contain antibiotic residues, which can enter the human bloodstream when consumed, further aggravating exposure. A recent study published in The Lancet Planetary Health stated that there are bidirectional associations between antibiotic consumption and AMR rates in humans and animals — that is, antibiotic use in animals can lead to AMR in humans, and vice versa. A separate study from 2015 estimated that nearly two-thirds of global antibiotic sales were for animal agriculture, with consumption projected to rise by another 67 per cent by 2030 due to increased demand for livestock products in low- and middle-income countries (LMICs). Coordinated action needed on new framework, says DCGI In a letter to all state and Union Territory (UT) drug controllers, Drug Controller General of India (DCGI) Rajeev Raghuvanshi called for coordinated action on AMU, specifically in the veterinary sector. The letter instructed all SLAs to nominate a nodal officer, not below the rank of assistant or joint drugs controller, to act as the point of contact for AMU data collection and coordination with the joint working group. It also asked state regulators to provide a comprehensive list of pharmaceutical companies involved in the manufacturing, distribution, and sale of veterinary antibiotics within their respective jurisdictions. In a separate letter dated 5 June, the DCGI also asked all zonal and sub-zonal offices of the CDSCO to share a list of approved drugs — including antibiotics, fixed drug combinations (FDCs), and their premixes — for veterinary use. A framework for AMU reporting is being seen as another key step to address AMR. Just last month, the central drug regulator released a draft guidance document for the safe disposal of unused or expired drugs, aimed at preventing AMR and other public health risks. The Centre had also urged pharmacists last year to dispense antibiotics only on the prescription of a qualified doctor, thereby limiting over-the-counter (OTC) sales. Under the Drugs and Cosmetics Rules, antibiotics are included in Schedule H — a list of drugs that may be sold by retail only on the prescription of a Registered Medical Practitioner (RMP).
